#SFHS2613353AFrance Adds Six Weight-Management Medicines to the Reimbursable Drugs List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France adds six pharmaceutical products to the list of medicines reimbursed by social health insurance, but only for a tightly defined weight-management use in adults. Coverage applies after well-managed nutritional care has failed, and only alongside a reduced-calorie diet and increased physical activity. The reimbursement is limited to adults with an initial BMI of at least 40, or at least 35 with listed obesity-related conditions such as type 2 diabetes, treated hypertension, severe sleep apnea, chronic kidney disease, NASH or liver fibrosis, severe asthma linked to obesity, fertility issues tied to assisted reproduction, or disabling joint and back conditions. Patients, prescribers, pharmacies, and insurers will need to check these criteria before coverage is claimed.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds six pharmaceutical specialties to France’s reimbursable medicines list.
- Limits reimbursement to adult weight-management treatment after failed nutritional care.
- Sets strict BMI and comorbidity criteria for insurance coverage.
Obligations
What this law requires
Limit reimbursement coverage for the listed pharmaceutical specialties to adult patients whose well-conducted nutritional management has failed, defined as less than 5% weight loss after six months, and only when treatment is used with a reduced-calorie diet and increased physical activity for weight management.
Verify that reimbursed adult patients without comorbidities had an initial BMI of at least 40 kg/m² before claiming or approving coverage for the listed pharmaceutical specialties.
Verify that reimbursed adult patients with comorbidities had an initial BMI of at least 35 kg/m² and at least one qualifying obesity-related comorbidity before claiming or approving coverage.
Do not treat isolated hepatic steatosis as a qualifying comorbidity for reimbursement eligibility; qualifying liver conditions are non-alcoholic steatohepatitis or hepatic fibrosis at any fibrosis stage.
For patients relying on chronic kidney disease as the qualifying comorbidity, obtain nephrologist advice for coverage eligibility up to moderate chronic kidney disease stage 3A or 3B.